Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi
Welcome,         Profile    Billing    Logout  
 12 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zamagni, Claudio
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
GOGER-01, NCT02125513 / 2013-002520-17: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer

Active, not recruiting
2
129
Europe
carboplatin and paclitaxel followed by surgery
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
05/21
12/23
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
GALENO 1, NCT04474951: Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

Recruiting
N/A
60
Europe
Stinging Nettle, Peppermint
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Breast Cancer, Gynecologic Cancer
03/21
09/21
Acu-CIPN, NCT05673746: Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer

Recruiting
N/A
102
Europe
Acupuncture, treatment of physician choice, according to the standard of care
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Peripheral Neuropathy
12/23
12/23
NCT04770376: Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab

Recruiting
N/A
150
Europe
Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale SS Giovanni e Paolo, Venezia
Ovarian Cancer
12/23
12/23
NCT06800612: Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

Recruiting
N/A
100
Europe
Oncologic drugs administered for treatment of breast cancer, Oncologic drug administered for treatment of gynecologic cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic, Ovarian Cancer, Cervical Carcinoma, Endometrial Cancer
12/30
12/30
BeLIVE, NCT06836219: Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Recruiting
N/A
300
Europe
Consorzio Oncotech
Ovarian Cancer
01/29
01/29
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
NCT02261389: Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET

Active, not recruiting
N/A
1507
Europe
Arm B, tumor markers assessment, CEA, CA15-3, 18FDG-PET
IRCCS Azienda Ospedaliero-Universitaria di Bologna, PONS-S (Patientenorientierte Nachsorge-Stiftung), Augsburg, Germany, Azienda ULSS 12 Veneziana, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer
11/26
12/30
Gelsomino, Francesco
ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting
2
33
Europe
Alectinib
Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer
12/24
12/26
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zamagni, Claudio
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Recruiting
3
250
Europe, Japan
Carboplatin, Paclitaxel
ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission
Ovarian Cancer
06/27
12/28
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
GOGER-01, NCT02125513 / 2013-002520-17: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer

Active, not recruiting
2
129
Europe
carboplatin and paclitaxel followed by surgery
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
05/21
12/23
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
GALENO 1, NCT04474951: Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies

Recruiting
N/A
60
Europe
Stinging Nettle, Peppermint
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Breast Cancer, Gynecologic Cancer
03/21
09/21
Acu-CIPN, NCT05673746: Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer

Recruiting
N/A
102
Europe
Acupuncture, treatment of physician choice, according to the standard of care
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Peripheral Neuropathy
12/23
12/23
NCT04770376: Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab

Recruiting
N/A
150
Europe
Observational study. Blood samples will be collected at scheduled blood draws performed as per clinical practice before each cycle of chemotherapy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale SS Giovanni e Paolo, Venezia
Ovarian Cancer
12/23
12/23
NCT06800612: Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

Recruiting
N/A
100
Europe
Oncologic drugs administered for treatment of breast cancer, Oncologic drug administered for treatment of gynecologic cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic, Ovarian Cancer, Cervical Carcinoma, Endometrial Cancer
12/30
12/30
BeLIVE, NCT06836219: Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Recruiting
N/A
300
Europe
Consorzio Oncotech
Ovarian Cancer
01/29
01/29
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
NCT02261389: Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET

Active, not recruiting
N/A
1507
Europe
Arm B, tumor markers assessment, CEA, CA15-3, 18FDG-PET
IRCCS Azienda Ospedaliero-Universitaria di Bologna, PONS-S (Patientenorientierte Nachsorge-Stiftung), Augsburg, Germany, Azienda ULSS 12 Veneziana, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer
11/26
12/30
Gelsomino, Francesco
ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting
2
33
Europe
Alectinib
Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer
12/24
12/26
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24

Download Options